Patient-Reported Tolerance of Magnetic Resonance-Guided Radiation Therapy.
MR-guided
MR-linac
patient tolerance
patient-reported outcomes
radiotherapy
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
06
05
2020
accepted:
11
08
2020
entrez:
19
10
2020
pubmed:
20
10
2020
medline:
20
10
2020
Statut:
epublish
Résumé
Magnetic resonance-guided radiation therapy (MRgRT) has been incorporated into a growing number of clinical practices world-wide, however, there is limited data on patient experiences with MRgRT. The purpose of this study was to prospectively evaluate patient tolerance of MRgRT using patient reported outcome questionnaires (PRO-Q). Ninety patients were enrolled in this prospective observational study and treated with MRgRT (MRIdian Linac System, ViewRay Inc. Oakwood Village, OH, United States) between September 2018 and September 2019. Breath-hold-gated dose delivery with audiovisual feedback was completed as needed. Patients completed an in-house developed PRO-Q after the first and last fraction of MRgRT. The most commonly treated anatomic sites were the abdomen (47%) and pelvis (33%). Respiratory gating was utilized in 62% of the patients. Patients rated their experience as positive or at least tolerable with mean scores of 1.0-2.8. The most common complaint was the temperature in the room (61%) followed by paresthesias (57%). The degree of anxiety reported by 45% of the patients significantly decreased at the completion of treatment (mean score 1.54 vs. 1.36, This evaluation of PROs indicates that MRgRT was well-tolerated by our patients. Patients' experience may further improve with adjustment of room temperature and noise reduction.
Identifiants
pubmed: 33072560
doi: 10.3389/fonc.2020.01782
pmc: PMC7537416
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1782Informations de copyright
Copyright © 2020 Sayan, Serbez, Teymur, Gur, Zoto Mustafayev, Gungor, Atalar and Ozyar.
Références
Phys Med. 2017 Dec;44:139-149
pubmed: 28242140
J Med Imaging Radiat Oncol. 2020 Feb;64(1):163-177
pubmed: 31646742
Semin Radiat Oncol. 2014 Jul;24(3):151-9
pubmed: 24931085
Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):933-941
pubmed: 30928360
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
J Natl Cancer Inst. 2014 Jul 08;106(7):
pubmed: 25006191
J Public Health (Oxf). 2005 Sep;27(3):281-91
pubmed: 15870099
Tumori. 2020 Feb 17;:300891620901752
pubmed: 32066345
Radiat Oncol. 2019 Jun 3;14(1):92
pubmed: 31167658
Clin Transl Radiat Oncol. 2018 Sep 05;14:1-7
pubmed: 30406210
Br J Radiol. 2020 Jan;93(1105):20190655
pubmed: 31670569
Cureus. 2019 Dec 24;11(12):e6457
pubmed: 32025388
Patient Prefer Adherence. 2013;7:259-68
pubmed: 23569365
Br J Radiol. 2006 Sep;79 Spec No 1:S2-15
pubmed: 16980682
Strahlenther Onkol. 2020 Aug;196(8):691-698
pubmed: 32002567
Cureus. 2018 Feb 27;10(2):e2236
pubmed: 29719739
J Cancer Res Ther. 2019 Jul-Sep;15(3):470-474
pubmed: 31169206
Eur J Cancer. 2019 Nov;122:42-52
pubmed: 31614288
Semin Radiat Oncol. 2014 Jul;24(3):227-32
pubmed: 24931098